ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Zymeworks Inc

Zymeworks Inc (ZYME)

6.43
0.00
(0.00%)
Closed April 23 4:00PM
6.43
0.00
( 0.00% )
Pre Market: 8:00PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
6.43
Bid
-
Ask
-
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Market Cap
Previous Close
6.43
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
-
Shares Outstanding
70,116,000
Dividend Yield
-
PE Ratio
-3.80
Earnings Per Share (EPS)
-1.69
Revenue
76.3M
Net Profit
-118.67M

About Zymeworks Inc

Zymeworks BC Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of different... Zymeworks BC Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its lead clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
North Vancouver, British Columbia, Can
Founded
1970

ZYME Latest News

Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers

Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers PR Newswire DUBLIN and VANCOUVER, BC...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.2988
(96.19%)
16.87M
AMSTAmesite Inc
$ 2.85
(42.50%)
1.9M
RILYB Riley Financial Inc
$ 28.61
(31.72%)
254.61k
IMCCIM Cannabis Corporation
$ 0.7268
(27.44%)
7
TSLRGraniteShares ETF Trust GraniteShares
$ 10.07
(24.17%)
6.11k
EVOEvotec SE
$ 5.25
(-31.37%)
144.24k
ESCAEscalade Inc
$ 10.35
(-24.78%)
11
TSDDGraniteShares ETF Trust GraniteShares
$ 26.911
(-24.19%)
22.76k
TSLZT Rex 2X Inverse Tesla Daily Target ETF
$ 42.65
(-23.73%)
302.36k
CDTGCDT Environmental Technology Investment Holdings Ltd
$ 3.03
(-19.41%)
22
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.2988
(96.19%)
16.87M
CYNCYNGN Inc
$ 0.114
(0.00%)
7.73M
ZPTAZapata Computing Holdings Inc
$ 1.83
(17.31%)
5.63M
PEGYPineapple Energy Inc
$ 0.0575
(1.59%)
5.07M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 6.67
(23.75%)
3.63M

ZYME Discussion

View Posts
Brokemillwright Brokemillwright 1 year ago
50 million complete...... 325 million potential by the end of 2022....... Yup, the pumpers didn't get rich overnight and went elsewhere.
πŸ‘οΈ0
Brokemillwright Brokemillwright 2 years ago
All the pumpers run away? Can't believe this wasn't praised

Zymeworks to receive $50 million upfront payment, a second payment of $325 million, at Jazz's option, and further potential regulatory and commercial milestones for total potential payments of up to $1.76 billion, plus royalties on net sales
πŸ‘οΈ0
Clean Clean 2 years ago
Its been holding up nicely here! Lets get some partnership payments!!!
πŸ‘οΈ0
DTGoody DTGoody 2 years ago
I believe it does still look promising my friend.
πŸ‘οΈ0
budgetthis budgetthis 2 years ago
Howdy ZYME’ers…….

The future still looks pretty good here, doesn’t it ?

I think so…..

$$ ZYME $$
πŸ‘οΈ0
DTGoody DTGoody 2 years ago
Looks like it June July calls may pay off after all. Tonight's news looks pretty good!
πŸ‘οΈ0
Clean Clean 2 years ago
Glad I waited. I as well didn't like the news that management wasn't even engaging ABF. Still bullish for the month of June though! Hope we get a dip before then!
πŸ‘οΈ0
DTGoody DTGoody 2 years ago
Zyme Rejects Offer. I am Glad I sold all of my calls on yesterday's rally for a small loss as my average was .71 cents. The news wasn't very promising to me when they stated they haven't even engaged with ZYME.

05/19/2022 14:40:30 Sold 22 ZYME Jul 15 2022 7.5 Call @ 0.55 $1,198.70

05/19/2022 14:08:09 Sold 78 ZYME Jul 15 2022 7.5 Call @ 0.6 $4,639.94
πŸ‘οΈ0
DTGoody DTGoody 2 years ago
ALL BLUE CAPITAL EXPANDS ITS LEADERSHIP TEAM TO SUPPORT PROPOSED ACQUISITION OF ZYMEWORKS INC.
1:01 pm ET May 19, 2022 (PR Newswire) Print
Siddhartha Mukherjee, MD, Hematology and Oncology Medical Expert, Rhodes Scholar and Pulitzer Prize Winning Author, Recently Joined All Blue as Medical Advisor

All Blue Urges Zymeworks Board to Engage with All Blue on Its Compelling $10.50 Per Share Acquisition Proposal, Consistent with the Board's Fiduciary Duties

All Blue Capital ("AB"), a global investment firm, today announced that Siddhartha Mukherjee, MD, Associate Professor of Medicine in the Division of Hematology/Oncology at Columbia University Medical Center in New York City, recently joined AB as Medical Advisor.

https://mma.prnewswire.com/media/1810200/All_Blue_Capital_Logo.jpg

As a Pulitzer Prize winning author, Rhodes Scholar and recipient of the Padma Shri, the fourth highest civilian award conferred by the Government of India, Dr. Mukherjee would apply his extensive medical expertise as a member of the Zymeworks (NYSE: ZYME) Board of Directors following a successful completion of AB's proposed $10.50 per share in cash acquisition of Zymeworks.

Dr. Mukherjee's arrival follows that of Dr. Alan Barge, the oncology and biopharmaceutical drug development expert who recently joined AB as Oncology Drug Development Advisor. It is expected that Dr. Mukherjee and Dr. Barge would both serve on Zymeworks' Board following the completion of the proposed acquisition.

Matt Novak, Managing Partner, All Blue Capital, said, "Dr. Mukherjee is a renowned physician, professor and author who has made countless contributions to better understanding the science of cancer and developing therapies. We believe that he will offer tremendous value in helping to correct many of the missteps that have recently plagued Zymeworks to the detriment of its shareholders."

Dr. Mukherjee joined the faculty at the Columbia University Medical Center as an assistant professor in 2009. Before that, he was affiliated with the Harvard Stem Cell Institute and with Massachusetts General Hospital in Boston. He has worked as the Plummer Visiting Professor at the Mayo Clinic in Rochester, Minnesota, the Joseph Garland lecturer at the Massachusetts Medical Society, and an honorary visiting professor at Johns Hopkins School of Medicine.

From 2003 to 2006, Dr. Mukherjee trained in oncology as a Fellow at the Dana-Farber Cancer Institute (under Harvard Medical School) in Boston, Massachusetts. Between 2000 and 2003, he worked as a resident in internal medicine at the Massachusetts General Hospital. In 2000, Dr. Mukherjee attended Harvard Medical School, where he earned his Doctor of Medicine degree. Dr. Mukherjee won a Rhodes Scholarship for doctoral research at Magdalen College, University of Oxford.

In 2011, Dr. Mukherjee's book, "The Emperor of All Maladies: A Biography of Cancer," won multiple, notable literary prizes, including the Pulitzer Prize for General Non-Fiction and the Guardian First Book Award, among others.

"Zymeworks has great potential to play an important role in the continued development of critical oncology and biopharmaceutical drugs. I strongly believe that we can take the necessary steps to help turnaround Zymeworks, while also advancing therapies to help combat cancer," said Dr. Mukherjee.

AB also announced today that it sent a letter to the Zymeworks Board urging it to respond to AB's April 28, 2022 proposal to acquire 100% of the outstanding common shares of the Company for $10.50 per share in cash. As outlined in the letter, the Board's continued silence and procrastination fits into an unfortunate pattern that has resulted from multiple attempts by AB to offer a constructive voice to the Company on matters that ultimately led to extreme value erosion.

Mr. Novak continued, "The Zymeworks Board's continued refusal to engage with All Blue on its acquisition proposal is surprising and disappointing. As a significant Zymeworks investor, we believe that Zymeworks shareholders deserve better than the consistent value destruction they have suffered. We continue to believe that our proposal would deliver compelling and immediate value to Zymeworks shareholders, and we would expect the Board to promptly engage with us to discuss the proposed transaction."

The letter states that AB maintains its belief that the Zymeworks Board should not continue to delay and obfuscate, but rather, should engage immediately with AB to discuss the proposal, in satisfaction of its fiduciary duties. The letter reiterates that if the Board continues to refuse to engage expeditiously and in good faith, AB expects to take action to protect shareholder interests, including taking the proposal directly to Zymeworks' shareholders.

The full content of AB's letter to the Zymeworks Board of Directors, dated May 19, 2022, is set forth below.

VIA EMAIL

May 19, 2022

Board of Directors Zymeworks Inc. 540-1385 West 8th Avenue Vancouver, BC V6H 3V9

Dear Members of the Board of Directors:

We are writing as a follow-up to our April 28, 2022 letter, in which we proposed to acquire 100% of the outstanding common shares of the Company for $10.50 per share in cash.

We have yet to receive a response from the Company to our proposal. Needless to say, the Board's lack of interest is surprising and disappointing. Given the compelling and immediate value that our proposal represents for Zymeworks shareholders, we would expect the Board to promptly engage with us to discuss the proposed transaction. Contrary to statements made by the Company on the May 4 2022 earnings call, our proposal is formal and requires timely review and response by the Board, in satisfaction of its fiduciary duties. We would also note that we have heard from multiple shareholders since we publicly announced our proposal, all of whom have expressed the view that a transaction based on the terms of our proposal would be highly attractive.

The Board's continued silence and procrastination fits into an unfortunate pattern. We have previously reached out multiple times in attempts to be a constructive voice for the Company, and the Board has refused to engage with us on any of the issues that we have raised.

On January 24, 2022, we approached the Board to express our concerns about the extreme value erosion that had resulted from many missteps and poor decisions by the Company. These included a number of missed deadlines that were publicly articulated in press releases, poorly executed conference calls, and confusing and mixed public messaging. In addition, we shared our concern over the Board's willingness to forgo proper corporate governance protocols to elect Kenneth Galbraith as both CEO and Chair of the Board. We did not receive a response to any of these concerns.

Two days later, on January 26, 2022, we approached the Board to express concern regarding the Company's plan for a public capital raise on terms that we believe were highly dilutive and contrary to the best interests of the Company and its shareholders. We had previously proposed to provide an equity financing solution to the Company, along with two alternative financing proposals, all of which were rejected without explanation.

Shortly thereafter, on February 4, 2022, after speaking with several other shareholders who were equally unhappy with the Company's decisions, we sent the Board a formal letter regarding these matters. However, we did not receive a response to this letter.

We would like to reiterate that, as a significant investor in the Company, we believe that Zymeworks shareholders deserve better than the consistent value destruction they have suffered. We urge the Board to work with us in good faith to maximize value for all Zymeworks stockholders. We remain confident in our ability to move quickly and efficiently toward consummating a transaction.

We sincerely hope the Board will not continue to delay and obfuscate and will engage with us immediately to discuss our proposal. We look forward to receiving a prompt response. As we stated in our April 28, 2022 letter, if the Board refuses to engage with us expeditiously and in good faith, we expect to take action to protect shareholder interests, including taking our proposal directly to Zymeworks' shareholders.

Sincerely,

Matthew Novak Managing Partner ALL BLUE FALCONS FZE

About All Blue

AB is a global investment firm that manages multiple alternative asset classes, including private equity, real estate, blockchain and hedge funds. Leveraging the strength of the team's global presence and through its strategic network of partners, AB is able to take advantage of differentiated investment opportunities across asset classes, industries and geographies. AB's focus on its core values of entrepreneurialism, innovation, and institutionalization has led to a history of delivering excellent risk-adjusted returns.

Media Contact

Jeremy Fielding / Richard Goldman Kekst CNC (646) 644-4825 / (646) 847-6102 ABMedia@kekstcnc.com

https://c212.net/c/img/favicon.png?sn=NY63742&sd=2022-05-19

View original content to download multimedia:https://www.prnewswire.com/news-releases/all-blue-capital-expands-its-leadership-team-to-support-proposed-acquisition-of-zymeworks-inc-301551476.html

SOURCE All Blue Capital

https://rt.prnewswire.com/rt.gif?NewsItemId=NY63742&Transmission_Id=202205191300PR_NEWS_USPR_____NY63742&DateId=20220519

comtex tracking
COMTEX_407464888/1005/2022-05-19T13:01:01
πŸ‘οΈ0
DTGoody DTGoody 2 years ago
We need to see a formal offer for this to be taken seriously.
πŸ‘οΈ0
DTGoody DTGoody 2 years ago
Moving in the right direction now!!!
πŸ‘οΈ0
DTGoody DTGoody 2 years ago
Loaded both June and July $7.50 calls! Let's make a deal!!! :))
πŸ‘οΈ0
DTGoody DTGoody 2 years ago
:))
πŸ‘οΈ0
Clean Clean 2 years ago
Dreamers gotta dream!!!

Bring on the $15!!!!!!!
πŸ‘οΈ0
DTGoody DTGoody 2 years ago
You Have a Good Day Too my Friend! I am holding 50 contracts of the June 7.50's which are do or die for me. I had 100 contracts, but I sold half at nearly a double from where I bought them down in the .50's the other day.

I really would love to see an earnings beat and maybe this stock explodes to $15 per share without a buyout? I know I am dreaming right! LOL
πŸ‘οΈ0
budgetthis budgetthis 2 years ago
Could be the fact Nick Abbott did the prognostication……lol.

But I bought a bunch of May 20th $7.50 call options cause I believe !!

Have a good day, DT !!

$$ ZYME $$
πŸ‘οΈ0
DTGoody DTGoody 2 years ago
Wells Fargo places a Buy rating of $45 per share for ZYME and the market is asleep???

Wells Fargo Sticks to Its Buy Rating for Zymeworks (ZYME)
May 04 2022 - 12:16AM
TipRanks
In a report released yesterday, Nick Abbott from Wells Fargo reiterated a Buy rating on Zymeworks (ZYME – Research Report), with a price target of $45.00. The company's shares closed last Tuesday at $7.15, close to its 52-week low of $4.56. According to TipRanks.com, Abbott has 0 stars on 0-5 stars ranking scale with an average return of -46.2% and a 0.0% success rate. Abbott covers the Healthcare sector, focusing on stocks such as TRACON Pharmaceuticals, Arcturus Therapeutics, and Alaunos Therapeutics. Currently, the analyst consensus on Zymeworks is a Strong Buy with an average price target of $23.20, which is a 256.9% upside from current levels.
https://www.tipranks.com/news/blurbs/wells-fargo-sticks-to-its-buy-rating-for-zymeworks-zyme?utm_source=advfn.com&utm_medium=referral
πŸ‘οΈ0
Clean Clean 2 years ago
ABF just strengthened the seriousness of their offer!
πŸ‘οΈ0
DTGoody DTGoody 2 years ago
We get a second Bidder and this goes Boom! We get good earnings and this goes Boom! Definitely looking good here my friend!
πŸ‘οΈ0
budgetthis budgetthis 2 years ago
Everyone wants a part of us !!

ZYME to the moon…….
πŸ‘οΈ0
DTGoody DTGoody 2 years ago
Good Afternoon my Friend! ZYME is looking Good! Just got back from some shopping and seen we hit over $7 a little while ago! Can't wait for this to really pop again!
πŸ‘οΈ0
budgetthis budgetthis 2 years ago
I just woke up from a hard West Coast horse riding weekend……lol…….

Hi DT !!

Go ZYME !
πŸ‘οΈ0
DTGoody DTGoody 2 years ago
ZYME is on Fire this Morning, and nobody is here! LOL
πŸ‘οΈ0
DTGoody DTGoody 2 years ago
ZYME Getting a nice Rip Here! Let's hope something with the buyout is happening?
πŸ‘οΈ0
Brokemillwright Brokemillwright 2 years ago
Well that's far from $50 lol
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
means its not binding

lol

no velcro or glue


comprende?
πŸ‘οΈ0
Pt3 Pt3 2 years ago
What non biding offer mean
πŸ‘οΈ0
DTGoody DTGoody 2 years ago
This would go over $10 instantly until the deal closes. Hopefully that is what happens, or someone else comes in with a better offer then that would send it higher. I can't imagine them saying no to a $10.50 cash buyout offer.
πŸ‘οΈ0
Pt3 Pt3 2 years ago
What happen if they accept the offer
πŸ‘οΈ0
DTGoody DTGoody 2 years ago
Same here got some $7.50's
πŸ‘οΈ0
Pt3 Pt3 2 years ago
Bought call for this
πŸ‘οΈ0
Laszlo1 Laszlo1 2 years ago
God is awesome !!
πŸ‘οΈ0
Laszlo1 Laszlo1 2 years ago
My friend I am familiar with that verse I can proudly say I read through the Bible once .
Every time gives me something new
It’s awesome
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
smart point
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
Thank You for the kind words

I appreciate them

and

if you like me you will love reading Jeremiah 29:11

Message in reply to:
Smart money I have been following you over 3 years quietly . I appreciate everything you do Your Alerts in the morning made me lots of money
Thank you
πŸ‘οΈ0
Laszlo1 Laszlo1 2 years ago
Smart money I have been following you over 3 years quietly . I appreciate everything you do Your Alerts in the morning made me lots of money
Thank you
πŸ‘οΈ0
crudeoil24 crudeoil24 2 years ago
Non binding offer! Now watch Zwork do shelf placement @ closing bell. lol.
πŸ‘οΈ0
dealerschool2006 dealerschool2006 2 years ago
1 year later??? lol...I was talking about the dead cat bounce last year...lol...already forgot about ZYME...
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
https://ih.advfn.com/stock-market/NYSE/zymeworks-ZYME/stock-news/87950474/zymeworks-confirms-receipt-of-unsolicited-non-bin
πŸ‘οΈ0
TheFinalCD TheFinalCD 2 years ago
$ZYME https://finance.yahoo.com/news/exclusive-blue-capital-773-million-203938213.html
πŸ‘οΈ0
Brokemillwright Brokemillwright 2 years ago
From a newsletter, stock hasn't been a performer bit it's more of a speculation play. Valued at $50 a share for buyout, but before the 100m offering they just did.

Large pharmaceutical firms see Zymeworks as one such potential takeover candidate. As we noted in October, it was recently approached about an acquisition valued at roughly $50 per share. Plus, the company just hired a new CEO with a strong background in dealmaking...
This month, Zymeworks announced that CEO Dr. Ali Tehrani is stepping down. Tehrani, who is also a co-founder of the company, has served as CEO since its inception in 2003. The board appointed Ken Galbraith to take his place beginning February 1.
Galbraith's background is telling. He has more than 30 years of experience in the life sciences industry and a notable background in venture capital. That means his skill set is more suitable to dealmaking than Tehrani's.
It makes perfect sense to have a CEO with technical skills like Tehrani's as a company develops its technology. But once that technology has matured, like Zymeworks' has over the past 19 years, a CEO with dealmaking skills like Galbraith's becomes more desirable.
πŸ‘οΈ0
Brokemillwright Brokemillwright 2 years ago
Offering complete, time to start climbing? Could be worth a small gamble in the mid 8s here
πŸ‘οΈ0
dealerschool2006 dealerschool2006 3 years ago
wow, quick rebound for ZYME !!!
πŸ‘οΈ0
dealerschool2006 dealerschool2006 3 years ago
ZYME panic sell after results reported...
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock